Enzyme or gene replacement therapy with acid α-glucosidase (GAA) has achieved only partial efficacy in Pompe disease. We evaluated the effect of adjunctive clenbuterol treatment upon cation-independent mannose-6-phosphate receptor (CI-MPR) mediated uptake and intracellular trafficking of GAA during muscle-specific GAA expression with an adeno-associated virus (AAV) vector in GAA knockout (KO) mice.
Introduction
Enzyme replacement therapy (ERT) with recombinant human acid α-glucosidase (GAA) has prolonged ventilator-free survival and muscle strength in patients with Pompe disease; however, the limitations of ERT have become increasingly evident and many patients eventually become ventilator-dependent. The enzyme dosages required for ERT in Pompe disease range up to 100-fold greater than those for other lysosomal disorders, which can be attributed at least in part to the large muscle mass and to the formation of anti-GAA antibodies. ERT depends upon the uptake of recombinant lysosomal enzymes by the cation-independent mannose-6-phosphate receptor (CI-MPR) at the plasma membrane and trafficking to the lysosomes, and CI-MPR is present at low levels in the skeletal muscle postnatally (1) .
Clenbuterol treatment has been previously shown to enhance the biochemical correction of muscle from ERT in GAA (KO) mice with Pompe disease (2); furthermore, clenbuterol at a lower dose and a second β2-agonist (albuterol) increased Rotarod latency and biochemical correction following β 2 -agonist treatment, in comparison with ERT alone (3) . Glycogen content was reduced significantly in all striated muscles evaluated with the exception of tibialis anterior by clenbuterol treatment, in comparison with ERT alone (3).
Both of the β 2 -agonists evaluated increased uptake of rhGAA in the cerebral and cerebellar hemispheres of the brain during ERT, and glycogen storage was reduced accordingly in the brain (3) . Furthermore, Western blot analysis revealed that clenbuterol treatment increased the signal for CI-MPR in the extensor digitalis longus (EDL) muscle, cerebellum, and cerebrum (3).
The effect of CI-MPR upon gene therapy has been evaluated by administering an adeno-associated virus (AAV) vector encoding human GAA driven by a liver-specific regulatory cassette (AAV-LSPhGAA) to establish a liver depot for GAA secretion. A low dose of AAV-LSPhGAA, 2x10 10 vector particles (vp), was injected intravenously to GAA-KO mice +/-clenbuterol treatment (4) . The effect of clenbuterol was evident, (4) . These data demonstrated a synergistic effect upon efficacy from AAV vector administration and clenbuterol treatment in mice with Pompe disease.
The direct transduction of non-dividing myofibers has a distinct advantage for the treatment of a myopathy such as Pompe disease, especially for AAV vectors that remain almost exclusively episomal and are lost from dividing hepatocytes in the liver (5, 6) . Muscle-restricted transgene expression with an AAV vector containing a muscle-specific regulatory cassette significantly reduced glycogen accumulations in the heart and skeletal muscle, while evading the transgene-directed T cell responses otherwise directed against GAA expressed with a constitutive regulatory cassette in adult GAA-KO mice (7, 8) . However, the dosage requirements to achieve biochemical correction of skeletal muscle were approximately 10-fold higher with the muscle-expressing vector, in comparison with the liver-expressing vector (8, 9) . Therefore, we have evaluated the effect of adjunctive β 2 -agonist therapy in combination with the muscle-expressing vector, thereby potentially reducing vector dosage requirements for the AAV vector by augmenting the trafficking of GAA to lysosomes.
Materials and Methods

Preparation of AAV vectors
The vector, AAV-MHCK7hGAApA contains the MHCK7 regulatory cassette, the human GAA cDNA, and a human growth hormone polyadenylation sequence flanked by the AAV2 terminal repeats (8) . Briefly, 293 cells were transfected with an AAV vector plasmid, the AAV packaging plasmid (10) (courtesy of Dr. James M. Wilson, University of Pennsylvania, Philadelphia, PA), and pAdHelper (Stratagene, La Jolla, CA). Cell Page 6 lysate was harvested 48 hours following infection and freeze-thawed 3 times, and isolated by sucrose cushion pelleting followed by two cesium chloride gradient centrifugation steps. AAV stocks were dialyzed against 3 changes of Hanks buffer, and aliquots were stored at -80 o C. The number of vector DNA containing-particles was determined by DNase I digestion, DNA extraction, and Southern blot analysis. All viral vector stocks were handled according to Biohazard Safety Level 2 guidelines published by the NIH.
Generation of muscle-specific CI-MPR-KO and DKO mouse models:
CI-MPR-KO mice were generated using a muscle-specific promoter (muscle creatine kinase; CK) and the cre/loxP conditional knock out system as described previously (11) . The muscle-specific CI-MPR-KO mice were crossed with GAA-KO mice to generate muscle-specific DKO mice. This mouse colony was subsequently screened to be GAA -/-, M6PR flox/flox and MCK-Cre positive. DKO mice were genotyped and bred as described (2) . At the indicated time points post-injection, tissue samples were obtained and processed as described below. All animal procedures were done in accordance with Duke University
Institutional Animal Care and Use Committee-approved guidelines.
In vivo evaluation of AAV vector-mediated efficacy
Clenbuterol (30 mg/L) was provided continuously from day 1 in the drinking water, and vector as administered on day 1 by intravenous injection. Rotarod testing was performed as described (12) . Wirehang testing was performed with a 0.5 cm mesh hardware cloth fixed to an 8 by 10 inch frame. Mice were placed on the wire mesh, which was slowly inverted 6 inches over a cage containing paper bedding. The latency, or time until the mouse fell off of the wire mesh, was recorded. GAA activity and glycogen content were analyzed as described (12) . Histologic processing and staining of brain was performed using a modified paraffin processing and staining protocol as previously described (13) . Quantification of vector DNA was performed as follows using primers for human GAA and mouse β -actin (14) . Plasmid DNA corresponding to 0.01 copy to 10 copies of human GAA gene (in 500 ng genomic DNA) was used in a standard curve.
LAMP2 detection by immunohistochemistry
Paraffin embedded sections were de-paraffinized, rehydrated, then blocked in PBS containing 5% chick serum and 0.1% Triton-X 100. Primary antibody for LAMP-2 (H4B4, Santa Cruz, 1:50) was applied overnight at 4 C. Chicken anti-mouse conjugated 488 (Invitrogen, 1:200) was used for detection and DAPI for counterstaining of nuclei. Five 40x images were acquired per slide for blinded counting of LAMP-2 positive muscle fibers.
Western Blotting
Protein was prepared by homogenization and sonication, as described for quantification of GAA and glycogen. From the protein samples, an aliquot was taken and protein concentration determined by BCA Kit mmol/l glycine, 15% v/v methanol). Following transfer, membranes were blocked in 5% milk in PBST.
Primary antibodies (AKT #2938, LC3B #2775, SQSTM1/p62 #5114, GAPDH #D16H11 from Cell Signalling Technologies) were added to the membranes in 1% w/v bovine serum albumin in PBST and incubated overnight at 4 °C. Membranes were washed 3 times in PBST, followed by incubation in anti-rabbit HRP conjugated secondary antibody (Sant Cruz Biotechnology Inc.) in 1% w/v bovine serum albumin in PBST for 1 hr at room temperature. Blots were again washed 3 times in PBST, and then once in PBS. Blots were developed with enhanced chemiluminescence system (GE Healthcare), and images acquired on a GelDoc XR+ imager (Bio-Rad).
Densitometry
Western blot bands were quantified using ImageJ software (NIH). LC3 turnover was analyzed by comparing the intensity of the LC3-II band to the internal control GAPDH, as is currently recommended practice. (1) Results were shown as mean ± SEM. Significance between conditions (p<0.05) was ascertained by twotailed t-test.
Results
Treatment with clenbuterol has increased CI-MPR expression in muscle accompanied by increased CI-MPR mediated uptake of GAA and trafficking to the lysosome, where GAA was activated to reduce lysosomal glycogen ( Figure 1A ). In order to study intracellular trafficking of GAA, a muscle-expressing AAV vector as pseudotyped as AAV8 (AAV2/8-MHCK7hGAApA) in a 5-fold lower quantity than was previously required to clear glycogen storage from the heart (8) was administered intravenously to adult GAA-KO mice (2x10 11 vp). Biochemical efficacy was demonstrated by increased GAA activity in skeletal muscle at 12 weeks following vector administration, in comparison with untreated GAA-KO mice ( Figure 1B) . Clenbuterol further elevated GAA activity in the heart and diaphragm, in comparison with the vector alone. The combination therapy increased GAA activity to greater than the level observed in wildtype mice; however, GAA activity remained lower than wildtype levels in skeletal muscle ( Figure 1B ). Vector administration reduced the glycogen content of the diaphragm, soleus, and EDL ( Figure 1C ). The addition of clenbuterol significantly reduced glycogen content in the heart and all skeletal muscles evaluated, in comparison with the vector alone. However, all groups of GAA-KO mice had higher glycogen content than wildtype mice (<0.1 μm glucose/mg protein).
The mean urinary glucose tetrasaccharide (Glc 4 ) biomarker of glycogen storage and turnover was significantly lower in GAA-KO mice following combination treatment compared with vector-only treated mice ( Figure 1D ). Urinary Glc 4 correlated with heart glycogen content (R 2 = 0.72) and not with muscle glycogen Page 9
( Figure 1E ), indicating a major effect upon the heart. These data suggested that the β 2 agonist treatment enhanced trafficking of GAA to lysosomes and activation within striated muscle, without increasing receptormediated uptake per se, in the context of muscle-specific GAA expression.
The dependence of efficacy from clenbuterol upon CI-MPR expression was evaluated in CI-MPR-KO/GAA-KO mice (double-KO/DKO mice) that lacked CI-MPR expression in muscle. GAA activity was only slightly increased by the addition of clenbuterol in diaphragm, while GAA activity remained unchanged in the heart and limb muscles (Figure 2A ). Glycogen content was only slight reduced in the quadriceps by the addition of clenbuterol, and unchanged in the heart and diaphragm ( Figure 2B ). Thus, the additional biochemical efficacy from clenbuterol administration seemed to depend upon CI-MPR expression, because GAA activity remained the same or increased only slightly following clenbuterol administration. The addition of clenbuterol had no effect upon glycogen storage in the heart and diaphragm of DKO mice; however, glycogen content was slightly reduced in all of the limb muscles by clenbuterol, which raised the possibility of an additional mechanism for its activity ( Figure 2B ). Vector DNA quantification was performed in heart to determine whether variability in transduction might underlie the differences between groups of mice;
however, no significant differences were observed between any of the treatment groups, indicating equivalent transgene delivery in all groups ( Figure 2C ). Given the partial biochemical response of the quadriceps and other limb muscles in absence of CI-MPR expression, LAMP2 vacuolization was analyzed as a marker for glycogen accumulation ( Figure 4A ). As expected, greater LAMP-2 expression was observed in GAA-KO mice compared to wild-type mice (15) .
Although vector treatment alone did not significantly decrease LAMP-2 expression, the addition of clenbuterol significantly reduced LAMP-2 expression ( Figure 4B ), which resembled that observed in wildtype animals ( Figure 4A ).
A dysregulation of macroautophagy, a process by which cytosolic components are sequestered and delivered to lysosomes, has long been implicated in the pathology of Pompe's disease (16) . Pompe disease is associated with an increase in the number of autophagosomes and a decrease in autophagic flux, as the lysosomal degradation of autophagosomal targets is impaired (17) . We thus investigated whether vector administration affected this abnormal autophagy [ Figure 5 ]. Treatment with the AAV vector significantly decreased the protein levels of LC3-II, a marker for autophagosomal formation ( Figure 5A and 5C) (18).
Moreover, this decrease was associated with an increase in autophagic flux, as the treatment also significantly decreased the abnormal accumulation of SQSTM1/p62 ( Figure 5A and 5B), implying an increase in autophagic flux (19) . Adjunctive treatment with clenbuterol caused a non-statistically significant increase in the levels of both LC3-II and SQSTM1/p62 compared with vector alone; however, when compared to the dramatic improvement seen in the clenbuterol-treated mice, it likely was not biologically significant. Furthermore, we investigated the AKT/mTOR pathway, which is known to inhibit autophagy (20) .
GAA-KO mice showed increased phosphorylation of AKT ( Figure 6A-C) , and the mTOR substrate p70s6k
( Figure 6D-F) , compared to the wild type mice. Vector administration significantly reduced both of these phosphorylations, which were further reduced with adjunctive clenbuterol treatment (Table) . Of note, the Page 11 reduction of AKT/mTOR signaling by clenbuterol did not seem to correlate with decreased p62 in the clenbuterol-treated mice (Table) , implying that any clenbuterol effect was mediated by a different pathway.
Discussion
The current study was designed to address the question of whether the increased CI-MPR expression associated with clenbuterol administration might improve the trafficking of GAA to lysosomes in mice with
Pompe disease, given the low expression of CI-MPR in striated muscle postnatally ( The increase in AKT and p70s6k in the GAA-KO mice that occurred after recovery from AAV treatment ( Figure 6 ) was an unexpected finding. Although we initially predicted that AKT levels should be higher in the treated mice, secondary to increased muscle mass and IGF-1 signaling (22), the opposite trend was observed. Only one previous study has investigated the role of AKT/mTOR in Pompe's disease, when
Nishiyama and colleagues found AKT signaling to be reduced in the fibroblasts of affected patients, with improvement in lysosomal delivery of GAA following activation of this pathway by insulin (23) . Although the results from our study seem to contradict these previous findings, it is important to note that fibroblasts and skeletal muscle may respond differently to the loss of GAA, and AKT may play different roles in different tissues. Another interesting finding is that the LC3-II levels were highly increased ( Figure 5C ) in the GAA-KO mice, which also showed increased mTOR signaling ( Figure 6 ). While mTOR has classically been known to inhibit the first step of autophagosomal formation, leading to a decrease in LC3-II protein levels (20) , a recent study has shown that it may also inhibit lysosomal activity as well (24) , and that effect may be predominating in this system. In our study, AAV vector transduction reduced the increased AKT signaling in GAA-KO mice, and the addition of clenbuterol further reduced pAKT (Table) . Thus, the effect of adding clenbuterol was to reduce the abnormalities of autophagy further, in comparison with partial correction from vector administration alone. Moreover, clenbuterol and AAV transduction further enhanced clearance of glycogen in limb muscles above the amount observed from AAV transduction in both GAA-KO and DKO mice. The observation that clenbuterol treatment reduced glycogen storage in DKO mice confirms that clenbuterol works independently of GAA to significantly reduce glycogen content in the skeletal muscles of mice with Pompe disease (3), because AAV transduction with GAA was ineffective in DKO mice (Figure 2) as described (4) . Furthermore, clenbuterol's observed effects on reducing mTor signaling and glycogen Page 13 content were similar to the reported effect of rapamycin, which inhibited mTor and reduced glycogen storage in the skeletal muscle of GAA-KO mice (25) .
Adjunctive therapy with clenbuterol was beneficial in combination with ERT or gene therapy (2-4) ; however, clinical translation of this strategy will depend upon the response of humans to clenbuterol. One critical factor will be the effective serum concentration of β2-agonists. Limited data are available, but the effective concentration (EC50) for clenbuterol was lower for humans and other higher mammals than for rodents. For example, the EC50 for clenbuterol for the relaxation of rat smooth muscle was approximately 10-fold higher than the EC50 for equine or human smooth muscle (26) (27) (28) . Moreover, the standard dosages of clenbuterol (Table) .
Our data also raise the intriguing possibility of further improving the treatment by using an mTOR inhibtor such as rapamycin in conjunction with clenbuterol as well as gene therapy. Previous work has shown a beneficial effect by gene therapy in combination with rapamycin (25) , as mTORC1 inhibition reduces glycogen synthesis. Additionally, mTORC1 inhibition increases the activity of TFEB (32), a transcription factor known as the master regulator of autophagosomal and lysosomal biosynthesis (33 Overall, our results suggest that the therapeutic role of clenbuterol can be expanded from the concept of enhanced receptor-mediated uptake of GAA to include enhanced trafficking of muscle-expressed GAA during gene therapy. Furthermore, its effects on autophagy, possibly through AKT signaling indicate the potential benefit from a second mechanism independent of CI-MPR in limb muscle. Ultimately, clenbuterol could be beneficial in patients with late-onset Pompe disease for whom ERT is not an option, because it could reduce glycogen storage in limb muscles and result in positive effects upon ambulation. Realtime PCR quantification of vector DNA in the heart (n=4 in each group for the latter analysis).. *=p<0.05; **=p<0.01, ***=p<0.001. 
